3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Small Cell Lung Carcinoma
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Interventions
Specimen Handling
278
Magnetic Resonance Spectroscopy
233
pembrolizumab
227
Carboplatin
187
Cisplatin
153
Biopsy
148
Cyclophosphamide
143
Paclitaxel
133
Nivolumab
122
Gemcitabine
113
Bevacizumab
104
Radiotherapy
92
Dexamethasone
86
Pemetrexed
83
fludarabine
77
Fluorouracil
76
Docetaxel
75
Doxorubicin
74
atezolizumab
71
Radiation
71
Leucovorin
70
Rituximab
67
Oxaliplatin
66
venetoclax
61
durvalumab
61
Prednisone
60
Vincristine
56
Cetuximab
56
Lenalidomide
54
Etoposide
54
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
BID protein, human
×
30 days
×
Clear all
NCT04624204
2026-05-26
MK 7339-013
Merck Sharp & Dohme LLC
Phase 3
Active not recruiting
672 enrolled